BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 31203104)

  • 1. The upregulation of Pim kinases is essential in coordinating the survival, proliferation, and migration of KIT D816V-mutated neoplastic mast cells.
    Park H; Kim D; Koh Y; Yoon SS
    Leuk Res; 2019 Aug; 83():106166. PubMed ID: 31203104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
    Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
    Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
    Gotlib J; Berubé C; Growney JD; Chen CC; George TI; Williams C; Kajiguchi T; Ruan J; Lilleberg SL; Durocher JA; Lichy JH; Wang Y; Cohen PS; Arber DA; Heinrich MC; Neckers L; Galli SJ; Gilliland DG; Coutré SE
    Blood; 2005 Oct; 106(8):2865-70. PubMed ID: 15972446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The transcriptome of the human mast cell leukemia cells HMC-1.2: an approach to identify specific changes in the gene expression profile in KitD816V systemic mastocytosis.
    Haenisch B; Herms S; Molderings GJ
    Immunol Res; 2013 May; 56(1):155-62. PubMed ID: 23504229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
    Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
    J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.
    Gabillot-Carré M; Lepelletier Y; Humbert M; de Sepuvelda P; Hamouda NB; Zappulla JP; Liblau R; Ribadeau-Dumas A; Machavoine F; Letard S; Baude C; Hermant A; Yang Y; Vargaftig J; Bodemer C; Morelon E; Lortholary O; Recher C; Laurent G; Dy M; Arock M; Dubreuil P; Hermine O
    Blood; 2006 Aug; 108(3):1065-72. PubMed ID: 16597595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
    Omori I; Yamaguchi H; Miyake K; Miyake N; Kitano T; Inokuchi K
    Exp Hematol; 2017 Aug; 52():56-64.e4. PubMed ID: 28506695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.
    Chaix A; Arcangeli ML; Lopez S; Voisset E; Yang Y; Vita M; Letard S; Audebert S; Finetti P; Birnbaum D; Bertucci F; Aurrand-Lions M; Dubreuil P; De Sepulveda P
    Oncogene; 2014 Feb; 33(7):872-81. PubMed ID: 23416972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
    Beghini A; Cairoli R; Morra E; Larizza L
    Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.
    Prats-Martín C; Jiménez-Guerrero P; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; Pérez O; Montero I; Falantes J; Burillo-Sanz S; Carrillo E; Borrero JJ; Bernal R; Pérez-Simón JA
    Ann Hematol; 2018 Mar; 97(3):533-535. PubMed ID: 29151134
    [No Abstract]   [Full Text] [Related]  

  • 13. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
    Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V.
    Noack F; Sotlar K; Notter M; Thiel E; Valent P; Horny HP
    Leuk Lymphoma; 2004 Nov; 45(11):2295-302. PubMed ID: 15512820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
    Yadav AK; Kumar V; Bailey DB; Jang BC
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.
    Harir N; Boudot C; Friedbichler K; Sonneck K; Kondo R; Martin-Lannerée S; Kenner L; Kerenyi M; Yahiaoui S; Gouilleux-Gruart V; Gondry J; Bénit L; Dusanter-Fourt I; Lassoued K; Valent P; Moriggl R; Gouilleux F
    Blood; 2008 Sep; 112(6):2463-73. PubMed ID: 18579792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
    Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
    Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.
    Kobayashi M; Kuroki S; Tanaka Y; Moriya Y; Kozutumi Y; Uehara Y; Ono K; Tamura K; Washizu T; Bonkobara M
    Eur J Haematol; 2015 Dec; 95(6):524-31. PubMed ID: 25684098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.